Eun-Mi Yu, MD
Medical Oncology · Fairfax, VANPI 1093941114
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Novartis at 36.8% of the total. Reporting peaked in 2023 at $3,841 and has fallen 93.2% since, to $260 in 2024.
Across 88 payments — averaging $75.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Astellas Pharma Global Development$1K
- E.r. Squibb & Sons, L.L.C.$525
- Seagen Inc.$366
- Johnson & Johnson$331
- Merck$263
- plus $1K from 25 others
Across 35 payments — averaging $14,926 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$376K
- AstraZeneca$110K
- AVEO Pharmaceuticals, Inc.$37K
What the payments were for
- Consulting fees$3,59454%
- Food & beverage$2,79142%
- Education$3004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $2,459 |
| Astellas Pharma Global Development | 1 | $1,494 |
| E.r. Squibb & Sons, L.L.C. | 13 | $525 |
| Seagen Inc. | 6 | $366 |
| Johnson & Johnson | 7 | $331 |
| Merck | 9 | $263 |
| AstraZeneca(2 entities) | 8 | $161 |
| Astellas Pharma US Inc | 3 | $126 |
| EMD Serono, Inc. | 1 | $120 |
| Taiho Oncology, Inc. | 2 | $104 |
| AVEO Pharmaceuticals, Inc. | 1 | $100 |
| Progenics Pharmaceuticals, Inc. | 1 | $98 |
| Myovant Sciences Inc. | 1 | $83 |
| Ipsen Biopharmaceuticals, Inc | 3 | $62 |
| Bristol Myers Squibb | 2 | $44 |
| Mylan Institutional Inc. | 2 | $35 |
| Incyte Corporation | 2 | $35 |
| Exelixis Inc. | 2 | $34 |
| Verastem, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $29 |
| Medtronic | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| Pfizer | 1 | $17 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| Tersera Therapeutics LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Sanofi | 1 | $13 |
| Dova Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,685 in reported general payments places this provider in the 70th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 71 | $715,566 |
| InlytaAxitinib | 30 | $580,065 |
| XtandiEnzalutamide | 52 | $557,643 |
| OrgovyxRelugolix | 179 | $489,458 |
| CabometyxCabozantinib S-Malate | 16 | $410,859 |
| Abiraterone Acetate | 52 | $81,258 |
| EliquisApixaban | 22 | $18,140 |
| Oxybutynin Chloride | 21 | $701 |
| Hydrocortisone | 28 | $575 |
| Bicalutamide | 26 | $406 |
| Prednisone | 81 | $329 |
| Gabapentin | 27 | $328 |
| Ondansetron Hcl | 15 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Eliquis | $17 | $598,20552 claims |
| Astellas Pharma US IncXtandi | $126 | $557,64352 claims |
| Exelixis Inc.Cabometyx | $34 | $410,85916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Fairfax
- Janakiraman SubramanianFairfax$562K
- Alexander SpiraFairfax$533K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Nagla Abdel KarimFairfax$131K
- Lauren MauroFairfax$53K
- Donald TrumpFairfax$20K
- Timothy CannonFairfax$11K
- Arthur WinerFairfax$10K
- Danijela JelovacFairfax$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.